Compile Data Set for Download or QSAR
Report error Found 1541 Enz. Inhib. hit(s) with Target = 'Ubiquitin carboxyl-terminal hydrolase 7'
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538576(CHEMBL4634092)
Affinity DataIC50: 0.160nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538560(CHEMBL4640002)
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538571(CHEMBL4635160)
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538572(CHEMBL4649132)
Affinity DataIC50: 0.260nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538575(CHEMBL4638458)
Affinity DataIC50: 0.320nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538562(CHEMBL4643330)
Affinity DataIC50: 0.380nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538578(CHEMBL4640729)
Affinity DataIC50: 0.390nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538579(CHEMBL4647217)
Affinity DataIC50: 0.440nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538582(CHEMBL4638998)
Affinity DataIC50: 0.780nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538570(CHEMBL4638573)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538563(CHEMBL4648116)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538564(CHEMBL4641569)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538583(CHEMBL4643112)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50514118(CHEMBL4590454)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of USP7 (unknown origin) using Ub-Rh110 substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538577(CHEMBL4648623)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50638865(CHEMBL5558202)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of USP7 (unknown origin) using Ub-Rh110 substrate by fluorescence based analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538567(CHEMBL4633860)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50465231(CHEMBL4288150 | US10766903, Example 30)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human USP7 using Ub-Rho110 as substrate by SPR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50608425(CHEMBL5281187)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human USP7 using Ub-Rho110 as substrate by fluorescence based SPR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538569(CHEMBL4644317)
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538581(CHEMBL4642862)
Affinity DataIC50: 2.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538568(CHEMBL4640563)
Affinity DataIC50: 3.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538565(CHEMBL4635798)
Affinity DataIC50: 4.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731252(US20250122223, Example 85)
Affinity DataIC50: 6nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731249(US20250122223, Example 82)
Affinity DataIC50: 6nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50465231(CHEMBL4288150 | US10766903, Example 30)
Affinity DataIC50: 6nMAssay Description:Inhibition of USP7 (unknown origin) by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2020
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50652792(CHEMBL3752910)
Affinity DataKd:  6.20nMAssay Description:Binding affinity to human USP7 incubated for 45 mins by Kinobead based pull down assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538574(CHEMBL4638688)
Affinity DataIC50: 6.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50602285(CHEMBL5182862)
Affinity DataIC50: 7.60nMAssay Description:Inhibition of full-length USP7 (unknown origin) using ubiquitin-rhodamine 110 as substrate preincubated for 30 mins followed by substrate addition an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538566(CHEMBL4632475)
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50602291(CHEMBL5200808)
Affinity DataIC50: 8.20nMAssay Description:Inhibition of full-length USP7 (unknown origin) using ubiquitin-rhodamine 110 as substrate preincubated for 30 mins followed by substrate addition an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538556(CHEMBL4646914)
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50538561(CHEMBL4642308)
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2021
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50602287(CHEMBL5184307)
Affinity DataIC50: 15nMAssay Description:Inhibition of full-length USP7 (unknown origin) using ubiquitin-rhodamine 110 as substrate preincubated for 30 mins followed by substrate addition an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731248(US20250122223, Example 81)
Affinity DataIC50: 15nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731174(US20250122223, Example 7)
Affinity DataIC50: 16nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731245(US20250122223, Example 78)
Affinity DataIC50: 16nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731177(US20250122223, Example 10)
Affinity DataIC50: 17nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731279(US20250122223, Example 112)
Affinity DataIC50: 18nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731181(US20250122223, Example 14)
Affinity DataIC50: 18nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50602280(CHEMBL5180062)
Affinity DataIC50: 18nMAssay Description:Inhibition of full-length USP7 (unknown origin) using ubiquitin-rhodamine 110 as substrate preincubated for 30 mins followed by substrate addition an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM50465231(CHEMBL4288150 | US10766903, Example 30)
Affinity DataIC50: 18nMAssay Description:Inhibition of full-length USP7 (unknown origin) using ubiquitin-rhodamine 110 as substrate preincubated for 30 mins followed by substrate addition an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2023
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM731240(US20250122223, Example 73)
Affinity DataIC50: 18nMAssay Description:Measurement of USP7 inhibitory activity. USP7 activity was monitored in a fluorescence polarisation (FP) homogeneous assay using the isopeptide ubiqu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM507637(US11046681, Example 165 | 1-(2,3-dihydro-1,4-benzo...)
Affinity DataIC50: 19.6nMAssay Description:USP7 activity was measured using Rhodamine-110 c-terminal labelled Ubiquitin as a substrate (Viva Biosciences). Incubation with USP7 results in the r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM581918(WO2023003973, Compound Table2.3)
Affinity DataIC50: 20nMAssay Description:Dilute the compounds to 400 x of the final desired highest inhibitor concentration in reaction by 100% DMSO. For all compounds, transfer the compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2023
Entry Details
WIPO WO2023003973

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM581919(WO2023003973, Compound Table2.4)
Affinity DataIC50: 20nMAssay Description:Dilute the compounds to 400 x of the final desired highest inhibitor concentration in reaction by 100% DMSO. For all compounds, transfer the compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2023
Entry Details
WIPO WO2023003973

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM581916(WO2023003973, Compound 130)
Affinity DataIC50: 20nMAssay Description:Dilute the compounds to 400 x of the final desired highest inhibitor concentration in reaction by 100% DMSO. For all compounds, transfer the compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2023
Entry Details
WIPO WO2023003973

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM581917(WO2023003973, Compound 136)
Affinity DataIC50: 20nMAssay Description:Dilute the compounds to 400 x of the final desired highest inhibitor concentration in reaction by 100% DMSO. For all compounds, transfer the compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2023
Entry Details
WIPO WO2023003973

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM581922(WO2023003973, Compound Table2.14)
Affinity DataIC50: 20nMAssay Description:Dilute the compounds to 400 x of the final desired highest inhibitor concentration in reaction by 100% DMSO. For all compounds, transfer the compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2023
Entry Details
WIPO WO2023003973

TargetUbiquitin carboxyl-terminal hydrolase 7(Human)
Rapt Therapeutics

Curated by ChEMBL
LigandPNGBDBM581923(WO2023003973, Compound Table2.16)
Affinity DataIC50: 20nMAssay Description:Dilute the compounds to 400 x of the final desired highest inhibitor concentration in reaction by 100% DMSO. For all compounds, transfer the compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/31/2023
Entry Details
WIPO WO2023003973

Displayed 1 to 50 (of 1541 total ) | Next | Last >>
Jump to: